Treatment trajectories and patterns following non-medical switching to biosimilar adalimumab in patients with hidradenitis suppurativa: a retrospective observational multicenter study from Saudi Arabia

Background Adalimumab is the first biologic approved for moderate-to-severe hidradenitis suppurativa (HS). Considering potential cost savings, real-world data evaluating the prescribing patterns following a switch from the originator in HS remain limited.Methods We conducted a retrospective multicen...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ahmed Alamer, Taibah AbuTaki, Shareefa Mohammed Alonaizi, Dalal Saadoun Alsaadoun, Mukhtar Alomar
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2026-12-01
Col·lecció:	Future Science OA
Matèries:	Hidradenitis suppurativa adalimumab biosimilar non-medical switching treatment escalation biologics real-world-study
Accés en línia:	https://www.tandfonline.com/doi/10.1080/20565623.2026.2694330
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!